Navigation Links
Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
Date:5/13/2008

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) today reported its financial results for the third quarter ended March 31, 2008 and announced new strategic objectives as part of a restructuring of its clinical-stage product portfolio and development programs. Palatin will continue to develop products targeting melanocortin and natriuretic receptors in the sexual dysfunction, obesity, and cardiovascular fields, including acute hospital care products for use in treatment of acute systemic hypertension, congestive heart failure and hemorrhagic shock. The restructuring focuses the Company's resources on the programs and opportunities that management believes are most likely to increase shareholder value. Additional details will be provided by management in a conference call today at 11:00 a.m. Eastern Time.

Strategic Restructuring

Palatin has undertaken a strategic restructuring with the following elements and objectives:

-- Following a detailed evaluation, including review of regulatory and

commercial information and data on its new melanocortin compounds under

development for sexual dysfunction, Palatin has discontinued

development of bremelanotide for the treatment of male and female

sexual dysfunction;

-- Developing bremelanotide as a therapeutic drug for treatment of

hemorrhagic shock and related indications (shock induced by blood loss,

such as secondary to surgery or trauma);

-- Initiating a Phase 2A study this quarter with PL-3994, Palatin's

natriuretic peptide receptor A agonist compound, in patients with

controlled hypertension;

-- Initiating a Phase 2A study of PL-3994 durin
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
2. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
3. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
4. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
5. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
7. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
8. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
9. Veran Medical Technologies Secures $4.75M in First Institutional Funding
10. Neurobiological Technologies Reports Third Quarter Financial Results
11. InSet Technologies Appoints Jon Tremmel to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade hypothermic storage and cryopreservation freeze ... and tissues  ("BioLife" or the "Company"), today announced that it ... 4, 2015 (the "Annual Meeting"). Because the expected ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ...
(Date:12/24/2014)... 2014 The report expects global cell isolation ... also provides a carefully analyzed data about the vital drivers, ... Full Copy of Report @ http://bit.ly/1yUxy0T , According ... keep witnessing growth at an impressive CAGR during near future. ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) fiscal year earnings release, CorVel,will be ... June 10th at 11:30 am Eastern Time., Event: ... Starck, President and CEO ... 11:30 am Eastern Time, Tuesday, June 10th, 2008, Login: ...
... Xceed,s Dr. David Englert and Dr. Zhe Zhang of Children,s Hospital of, ... ... 21st, WELLESLEY, ... easy-to-use gene-expression analysis,systems, announced that the company will feature its Ziplex Automated,Gene-Expression ...
... China, May 16 /Xinhua-PRNewswire-FirstCall/ --,China Pharma Holdings, ... develops, manufactures, and markets generic and brand,bio-pharmaceutical ... donated 2,million RMB (approximately US$285,714) worth of ... medicines to help disaster relief in,China after ...
Cached Biology Technology:CorVel Corporation Announces Earnings Release Webcast 2Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16 2China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief 2
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Italian research team, publishing in the current issue of ... on-line without charge at http://www.ingentaconnect.com/content/cog/ct , has found ... play a role in the treatment of lung diseases, ... tuberculosis, chemical exposure, radiation or pathogens. These diseases can ...
... Muscular Atrophy is the second-leading cause of infant mortality in ... at Iowa State University,s College of Veterinary Medicine, would like ... even slide off the list altogether. , Most Spinal Muscular ... mutated or deleted gene called Survival Motor Neuron 1 (SMN1) ...
... at Penn State University, in collaboration with institutes in the ... long-sought structure of a layer of C60 carbon buckyballs ... help in the design of carbon nanostructure-based electronics are reported ... July 27th issue of APS,s on-line journal Physics ...
Cached Biology News:Placenta-derived stem cells may help sufferers of lung diseases 2ISU researchers find possible treatment for spinal muscular atrophy 2
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Wnt-1 (G-19)...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
Biology Products: